Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Antibiotic therapy in leukopenia]

A Böhme1, P M Shah, W Stille

  • 1Med. Klinik III, J.-W.-Goethe-Universität, Frankfurt/M.

Praxis
|October 23, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ESMO Clinical Practice Guideline interim update on the use of targeted therapy in acute lymphoblastic leukaemia.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia.

Blood cancer journal·2016
Same author

Prof. Thomas Büchner (22 September 1934-5 August 2016)-A leading European hematologist and AML trialist.

Leukemia·2016
Same author

Detection of Minimal Residual Disease in Adult Acute Lymphoblastic Leukemia by Analysis of Gene Rearrangements and Correlation with Early Relapses.

Leukemia & lymphoma·2016
Same author

Change in prognostic factors.

Leukemia supplements·2016
Same author

Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2016

Managing chemotherapy-induced neutropenia in hematologic malignancies requires prompt antimicrobial therapy and diagnostics. Early antifungal treatment is crucial for patients with pulmonary infiltrates to reduce mortality.

Area of Science:

  • Hematology
  • Infectious Diseases
  • Oncology

Context:

  • Chemotherapy for hematologic malignancies often causes prolonged neutropenia, increasing patient morbidity and mortality.
  • Current prophylactic standards include Co-Trimoxazole, fluoroquinolones, and oral amphotericin B.
  • Effective neutropenia management relies on hygiene, antimicrobial prophylaxis, therapy, and diagnostics.

Purpose:

  • To outline current best practices for managing neutropenia and febrile neutropenia in patients with hematologic malignancies.
  • To emphasize the importance of empirical broad-spectrum antibiotic therapy for febrile episodes.
  • To highlight the benefits of early antifungal intervention in specific patient subgroups.

Summary:

  • Intensified chemotherapy-induced neutropenia is a significant cause of morbidity and mortality in hematologic malignancies.

Related Experiment Videos

  • Empirical broad-spectrum antibiotic therapy is the standard initial treatment for febrile neutropenia, with modifications and antifungal addition recommended for non-responders.
  • Early amphotericin B treatment is advantageous for patients with pulmonary infiltrates, while the role of G-CSF/GM-CSF remains debated.

    • Impact:

    • Optimizing neutropenia management can significantly reduce infection-related mortality in hematologic cancer patients.
    • Adherence to evidence-based guidelines for febrile neutropenia treatment is critical for patient outcomes.
    • Further research may clarify the role of growth factors in supporting neutropenic patients.